Kristin Renee Hobbie

Works (1)

Updated: July 5th, 2023 15:50

2009 journal article

Toward a molecular equivalent dose: Use of the medaka model in comparative risk assessment

Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology, 149(2), 141–151.

By: K. Hobbie n, A. DeAngelo*, L. King*, R. Winn* & J. Law n

author keywords: Risk assessment; Dose-response; DNA; Medaka; cll; Mutation; Adduct; DMN; Nitrosamines
MeSH headings : Animals; Animals, Genetically Modified; Carcinogens / metabolism; Carcinogens / pharmacology; Carcinogens / toxicity; DNA / genetics; DNA / isolation & purification; DNA Adducts / analysis; DNA Adducts / metabolism; Dimethylnitrosamine / metabolism; Dimethylnitrosamine / pharmacology; Dimethylnitrosamine / toxicity; Dose-Response Relationship, Drug; Guanine / analogs & derivatives; Guanine / analysis; Guanine / metabolism; Immunohistochemistry; Liver / drug effects; Liver / metabolism; Liver / pathology; Male; Models, Biological; Mutagenicity Tests; Mutation; Oryzias / genetics; Random Allocation; Rats; Rats, Inbred F344; Rats, Transgenic; Risk Assessment; Water Supply
TL;DR: While liver DNA adduct concentrations were similar in magnitude, mutant frequencies in the DMN-exposed medaka were up to 20 times higher than in the Big Blue rats, and future work with other compounds will generate a more complete picture of comparative dose response between different phyletic levels and will help guide risk assessors using "Alternative" models. (via Semantic Scholar)
UN Sustainable Development Goals Color Wheel
UN Sustainable Development Goal Categories
Sources: Web Of Science, Crossref
Added: August 6, 2018

Citation Index includes data from a number of different sources. If you have questions about the sources of data in the Citation Index or need a set of data which is free to re-distribute, please contact us.

Certain data included herein are derived from the Web of Science© and InCites© (2025) of Clarivate Analytics. All rights reserved. You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.